
HUTCHMED (HCM) has gained 10.8% in the last four weeks, with Wall Street analysts projecting a mean price target of $25.75, suggesting a 73.5% upside from its current $14.84 close. While analyst price targets often warrant skepticism due to potential biases, the more compelling indicator for HCM's potential upside is the significant upward trend in earnings estimate revisions, with the Zacks Consensus Estimate for the current year increasing 39.5% over the past month, coupled with a Zacks Rank #2 (Buy), signaling strong agreement among analysts regarding improved earnings prospects.
HUTCHMED (HCM) exhibits a dual-signal profile characterized by strong near-term momentum and positive earnings revisions, contrasted with highly dispersed analyst price targets. The stock has appreciated 10.8% over the last four weeks to $14.84. While the mean analyst price target of $25.75 suggests a significant 73.5% upside, the underlying estimates are widely spread, ranging from $18.00 to $39.00 with a high standard deviation of $9.71, indicating considerable disagreement on valuation. A more compelling bullish indicator is the positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 39.5% over the past month, based on one upward revision and no downward revisions. This, combined with a Zacks Rank #2 (Buy), provides a more fundamentally-grounded signal of potential near-term price appreciation, as empirical research suggests a stronger correlation between earnings revisions and stock performance than with analyst price targets alone.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment